Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qingdao Haier Biomedical CoSHSE:688139 +1.04%82 EV-to-FCF is 56.71 as of Jul. 30, 2026, which is 8% below its 10-year median of 61.44. GuruFocus rates SHSE:688139 with a GF Score™ of 82/100 and a GF Value™ of ¥36.05 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 417 Medical Devices & Instruments companies, Qingdao Haier Biomedical Co ranks worse than 80.34% on this metric.
The historical rank and industry rank for Qingdao Haier Biomedical Co's EV-to-FCF or its related term are showing as below:
SHSE:688139'
s EV-to-FCF Range Over the Past 10 Years
Min: 23.86 Med: 61.44 Max: 328.11
Current: 55.36
During the past 10 years, the highest EV-to-FCF of Qingdao Haier Biomedical Co was 328.11. The lowest was 23.86. And the median was 61.44.
SHSE:688139's EV-to-FCF is ranked worse than 80.34% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.7
vs SHSE:688139: 55.36
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Qingdao Haier Biomedical Co (SHSE:688139) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Qingdao Haier Biomedical Co's PE Ratio (TTM) for today is calculated as:
Qingdao Haier Biomedical Co's share price for today is ¥28.18.
Qingdao Haier Biomedical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Qingdao Haier Biomedical Co EV-to-FCF Related Terms
Qingdao Haier Biomedical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688139 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Qingdao Haier Biomedical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qingdao Haier Biomedical Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qingdao Haier Biomedical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Qingdao Haier Biomedical Co's EV-to-FCF falls into.
Qingdao Haier Biomedical Co's current Enterprise Value is ¥7,691 Mil.
Qingdao Haier Biomedical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥136 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qingdao Haier Biomedical Co (SHSE:688139) has a EV-to-FCF of 56.71 as of Jul. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Qingdao Haier Biomedical Co and its competitors. This is near median its historical median of 61.44. Over the past decade, Qingdao Haier Biomedical Co's EV-to-FCF has ranged from 23.86 to 328.11. According to the industry distribution chart, Qingdao Haier Biomedical Co ranks #335 out of 417 companies in the Medical Devices & Instruments industry, placing it in the top 80.3%.
Is Qingdao Haier Biomedical Co's EV-to-FCF too high?
Qingdao Haier Biomedical Co's current EV-to-FCF of 56.71 is near median its 10-year median of 61.44. Over the past 10 years, this metric has ranged from a low of 23.86 to a high of 328.11. The Medical Devices & Instruments industry median EV-to-FCF is 23.70. Qingdao Haier Biomedical Co's value of 56.71 is 139.3% above this industry median. Based on the distribution chart, Qingdao Haier Biomedical Co ranks #335 out of 417 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Qingdao Haier Biomedical Co has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qingdao Haier Biomedical Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qingdao Haier Biomedical Co ranks #335 out of 417 companies for EV-to-FCF. This places Qingdao Haier Biomedical Co in the lower half of its industry. The industry median EV-to-FCF is 23.70. Qingdao Haier Biomedical Co's value of 56.71 is 139.3% above this benchmark. Historically, Qingdao Haier Biomedical Co's own EV-to-FCF has ranged from 23.86 to 328.11 over the past decade. While the company's 10-year median is 61.44 vs. the industry median of 23.70, Qingdao Haier Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.70, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qingdao Haier Biomedical Co's current EV-to-FCF of 56.71 is 139.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Qingdao Haier Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qingdao Haier Biomedical Co's current EV-to-FCF is 56.71, which is near median its own 10-year median of 61.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qingdao Haier Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Qingdao Haier Biomedical Co (SHSE:688139) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥36.05, compared to a current price of ¥28.18 — trading 21.8% below its estimated fair value. The current EV-to-FCF is 56.71, which is near median its 10-year median of 61.44 and 139.3% above the Medical Devices & Instruments industry median of 23.70. Qingdao Haier Biomedical Co's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Qingdao Haier Biomedical Co (SHSE:688139), the current EV-to-FCF is 56.71 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qingdao Haier Biomedical Co (SHSE:688139) Overvalued in 2026?
Based on GuruFocus' analysis, Qingdao Haier Biomedical Co stock appears to be undervalued.
The current stock price of ¥28.18 is trading 21.8% below its estimated GF Value™ of ¥36.05.
GuruFocus considers Qingdao Haier Biomedical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688139:
EV-to-FCF: 56.71 (near median its 10-year median of 61.44)
GF Value™: ¥36.05 vs. price of ¥28.18 (21.8% below fair value)
Industry Position: 139.3% above the Medical Devices & Instruments median (#335 of 417)
No single metric tells the full story. See the SHSE:688139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qingdao Haier Biomedical Co Ltd is engaged in designing, manufacturing, marketing and sales of low temperature storage equipment for biomedical samples. The company provides provides complete storage solutions for biological sample banks, blood safety, vaccine safety, medical supplies and reagent safety.
82GF Score
Get the complete analysis for SHSE:688139
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688139 has been successfully added to your 
